Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;7(13):292.
doi: 10.21037/atm.2019.05.29.

Pompe disease: what are we missing?

Benedikt Schoser  1
Affiliations
Review

Pompe disease: what are we missing?

Benedikt Schoser. Ann Transl Med. 2019 Jul.

Abstract

Pompe disease is a multisystemic metabolic disorder caused by a deficiency of lysosomal acid alpha-glucosidase (GAA) leading to progressive accumulation of lysosomal glycogen, lysosomal swelling and rupture in all tissues of the human body. Furthermore, autophagic buildup, organelle abnormalities, and energy deficit are regularly observed. Enzyme replacement therapy has been available for patients living with Pompe disease for more than 15 years. Although our disease knowledge has grown enormously, we still have multiple challenges to overcome. Here, I will discuss unmet clinical needs, neglected or overlooked aspects of the pathophysiology, and issues related to future therapies.

Keywords: Pompe disease; axial myopathy; energy metabolism; enzyme replacement therapy (ERT); fatigue; gene therapy; unmet needs.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: B Schoser has received advisory board membership honoraria and speaker fees from Genzyme Sanofi, Audentes therapeutic, Amicus therapeutics, Vertex therapeutics, and Valerion therapeutics. B Schoser has unrestricted grants from Sanofi Genzyme and Greenovation biopharma.

References

    1. Martiniuk F, Bodkin M, Tzall S, et al. Identification of the base-pair substitution responsible for a human acid alpha glucosidase allele with lower 'affinity' for glycogen (GAA 2) and transient gene expression in deficient cells. Am J Hum Genet 1990;47:440-5. - PMC - PubMed
    1. Wokke JH, Ausems MG, van den Boogaard MJ, et al. Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 1995;38:450-4. 10.1002/ana.410380316 - DOI - PubMed
    1. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006;86:1208-20. 10.1038/labinvest.3700484 - DOI - PubMed
    1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372:1342-53. 10.1016/S0140-6736(08)61555-X - DOI - PubMed
    1. Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev 2017;11:CD011539. - PMC - PubMed